To include your compound in the COVID-19 Resource Center, submit it here.

MGCD265: Phase I amended

MethylGene said it amended the ongoing, open-label, dose-escalation Phase I (Trial 101) trial evaluating once- and twice-daily

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE